Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more
Pacira BioSciences, Inc. (PCRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.063x
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has a cash flow conversion efficiency ratio of 0.063x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.69 Million) by net assets ($693.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pacira BioSciences, Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pacira BioSciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacira BioSciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jizhong Energy Resources Co Ltd
SHE:000937
|
0.023x |
|
Xtep International Holdings Limited
F:4QI
|
0.013x |
|
Smartgroup Corporation Ltd
PINK:STGXF
|
0.253x |
|
Information Services International-Dentsu Ltd
OTCGREY:IFMNF
|
N/A |
|
Theon International Plc
AS:THEON
|
-0.012x |
|
ScanSource Inc
NASDAQ:SCSC
|
0.025x |
|
Fortune Real Estate Investment Trust
PINK:FRIVF
|
0.010x |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
0.037x |
Annual Cash Flow Conversion Efficiency for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacira BioSciences, Inc. from 2008 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $693.11 Million | $151.99 Million | 0.219x | -9.88% |
| 2024-12-31 | $778.35 Million | $189.39 Million | 0.243x | +36.90% |
| 2023-12-31 | $870.13 Million | $154.65 Million | 0.178x | -5.18% |
| 2022-12-31 | $775.01 Million | $145.27 Million | 0.187x | +8.91% |
| 2021-12-31 | $730.41 Million | $125.72 Million | 0.172x | +38.46% |
| 2020-12-31 | $619.69 Million | $77.03 Million | 0.124x | -37.43% |
| 2019-12-31 | $354.94 Million | $70.52 Million | 0.199x | +30.59% |
| 2018-12-31 | $321.23 Million | $48.87 Million | 0.152x | +139.07% |
| 2017-12-31 | $279.48 Million | $17.79 Million | 0.064x | -58.35% |
| 2016-12-31 | $218.98 Million | $33.45 Million | 0.153x | +15.06% |
| 2015-12-31 | $218.39 Million | $29.00 Million | 0.133x | -10.78% |
| 2014-12-31 | $171.15 Million | $25.47 Million | 0.149x | +114.20% |
| 2013-12-31 | $41.25 Million | $-43.22 Million | -1.048x | +1.62% |
| 2012-12-31 | $65.86 Million | $-70.13 Million | -1.065x | -65.81% |
| 2011-12-31 | $48.27 Million | $-31.00 Million | -0.642x | -224.89% |
| 2010-12-31 | $-48.38 Million | $-24.88 Million | 0.514x | -43.37% |
| 2009-12-31 | $-22.95 Million | $-20.84 Million | 0.908x | +123.30% |
| 2008-12-31 | $7.49 Million | $-29.19 Million | -3.897x | -- |